Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (10): 1053-1055.DOI: 10.3969/j.issn.1673-8640.2020.10.021
Previous Articles Next Articles
Received:2019-12-03
Online:2020-10-30
Published:2020-11-12
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.10.021
| 组别 | PT/s | APTT/s | TT/s | Fib/ （g/L） | DD/ （μg/mL） | AT/% | PLT计数/ （×109/L） | PCT/ （ng/mL） | APACHEⅡ评分/分 |
|---|---|---|---|---|---|---|---|---|---|
| 脓毒症组 | 22.65±7.29 | 141.85±41.56 | 18.87±2.10 | 3.34±1.03 | 0.93±0.26 | 48.27±18.76 | 166.49±17.31 | 3.58±28.54 | 26.85±5.62 |
| 非脓毒症组 | 13.47±2.62 | 35.63±7.59 | 14.21±3.77 | 2.39±1.21 | 5.88±2.63 | 70.52±19.75 | 262.50±59.17 | 0.06±0.02 | 11.64±5.28 |
| t值 | 2.149 | 1.678 | 0.875 | 0.707 | 4.678 | -4.172 | -5.719 | 15.612 | 4.157 |
| P值 | 0.017 | 0.029 | 0.031 | 0.001 | <0.000 1 | <0.000 1 | 0.001 | <0.000 1 | <0.000 1 |
| 组别 | PT/s | APTT/s | TT/s | Fib/ （g/L） | DD/ （μg/mL） | AT/% | PLT计数/ （×109/L） | PCT/ （ng/mL） | APACHEⅡ评分/分 |
|---|---|---|---|---|---|---|---|---|---|
| 脓毒症组 | 22.65±7.29 | 141.85±41.56 | 18.87±2.10 | 3.34±1.03 | 0.93±0.26 | 48.27±18.76 | 166.49±17.31 | 3.58±28.54 | 26.85±5.62 |
| 非脓毒症组 | 13.47±2.62 | 35.63±7.59 | 14.21±3.77 | 2.39±1.21 | 5.88±2.63 | 70.52±19.75 | 262.50±59.17 | 0.06±0.02 | 11.64±5.28 |
| t值 | 2.149 | 1.678 | 0.875 | 0.707 | 4.678 | -4.172 | -5.719 | 15.612 | 4.157 |
| P值 | 0.017 | 0.029 | 0.031 | 0.001 | <0.000 1 | <0.000 1 | 0.001 | <0.000 1 | <0.000 1 |
| 组别 | 例数 | 未发生DIC/例（%） | 发生DIC/例（%） |
|---|---|---|---|
| A组 | 30 | 27（90.00） | 3（10.00）* |
| B组 | 15 | 11（73.33） | 4（26.67）* |
| C组 | 55 | 30（54.55） | 25（45.45） |
| 组别 | 例数 | 未发生DIC/例（%） | 发生DIC/例（%） |
|---|---|---|---|
| A组 | 30 | 27（90.00） | 3（10.00）* |
| B组 | 15 | 11（73.33） | 4（26.67）* |
| C组 | 55 | 30（54.55） | 25（45.45） |
| 组别 | 例数 | PLT计数/ （×109/L） | DD/ （μg/mL） | AT/% | Fib/ （g/L） | PT/s | APTT/s | 28 d死亡率/例（%） |
|---|---|---|---|---|---|---|---|---|
| A组 | 30 | 208.33±46.13 | 2.64±2.32 | 53.81±9.48 | 3.04±1.01 | 14.72±1.49 | 42.87±7.62 | 7（23.33） |
| B组 | 15 | 179.65±123.29 | 5.56±4.46 | 44.11±7.89 | 3.48±1.74 | 19.43±6.72 | 43.52±10.78 | 5（33.33） |
| C组 | 55 | 101.16±89.28 | 10.78±4.57 | 39.34±13.19 | 3.82±2.62 | 22.89±2.62 | 50.84±9.18 | 31（56.36） |
| 统计值 | 4.827 | 4.216 | 1.288 | -0.785 | -5.671 | 0.120 | 9.815 | |
| P值 | 0.028 | 0.004 | 0.037 | 0.675 | 0.031 | 0.049 | <0.000 1 |
| 组别 | 例数 | PLT计数/ （×109/L） | DD/ （μg/mL） | AT/% | Fib/ （g/L） | PT/s | APTT/s | 28 d死亡率/例（%） |
|---|---|---|---|---|---|---|---|---|
| A组 | 30 | 208.33±46.13 | 2.64±2.32 | 53.81±9.48 | 3.04±1.01 | 14.72±1.49 | 42.87±7.62 | 7（23.33） |
| B组 | 15 | 179.65±123.29 | 5.56±4.46 | 44.11±7.89 | 3.48±1.74 | 19.43±6.72 | 43.52±10.78 | 5（33.33） |
| C组 | 55 | 101.16±89.28 | 10.78±4.57 | 39.34±13.19 | 3.82±2.62 | 22.89±2.62 | 50.84±9.18 | 31（56.36） |
| 统计值 | 4.827 | 4.216 | 1.288 | -0.785 | -5.671 | 0.120 | 9.815 | |
| P值 | 0.028 | 0.004 | 0.037 | 0.675 | 0.031 | 0.049 | <0.000 1 |
| 组别 | 例数 | PT/s | APTT/s | TT/s | Fib/（g/L） | DD/（μg/mL） | AT/% | PLT计数/（×109/L） |
|---|---|---|---|---|---|---|---|---|
| 发生DIC组 | 32 | 21.39±4.36 | 49.34±11.21 | 17.89±2.55 | 3.34±0.15 | 9.78±4.62 | 45.29±14.18 | 71.36±19.68 |
| 未发生DIC组 | 68 | 13.58±4.63 | 35.63±8.71 | 13.21±4.16 | 4.39±1.22 | 6.82±3.06 | 63.61±20.75 | 195.69±111.69 |
| t值 | 2.032 | 1.876 | 1.275 | -0.717 | 1.678 | -3.152 | -5.788 | |
| P值 | 0.024 | 0.034 | 0.040 | 0.714 | 0.035 | 0.029 | <0.000 1 |
| 组别 | 例数 | PT/s | APTT/s | TT/s | Fib/（g/L） | DD/（μg/mL） | AT/% | PLT计数/（×109/L） |
|---|---|---|---|---|---|---|---|---|
| 发生DIC组 | 32 | 21.39±4.36 | 49.34±11.21 | 17.89±2.55 | 3.34±0.15 | 9.78±4.62 | 45.29±14.18 | 71.36±19.68 |
| 未发生DIC组 | 68 | 13.58±4.63 | 35.63±8.71 | 13.21±4.16 | 4.39±1.22 | 6.82±3.06 | 63.61±20.75 | 195.69±111.69 |
| t值 | 2.032 | 1.876 | 1.275 | -0.717 | 1.678 | -3.152 | -5.788 | |
| P值 | 0.024 | 0.034 | 0.040 | 0.714 | 0.035 | 0.029 | <0.000 1 |
| [1] | IBA T,GANDO S,SAITOH D,et al.Efficacy and bleeding risk of antithrombin supplementation in patients with septic disseminated intravascular coagulation:a third survey[J]. Clin Appl Thromb Hemost,2017,23(5):422-428. |
| [2] | 于佳,陈淘江,王冬梅,等. 炎症因子、凝血指标和内皮细胞损伤标记物在恶性血液病脓毒症早期诊断中的应用?[J]. 肿瘤预防与治疗,2019,32(8):688-693. |
| [3] | 张宇,梁志锋,徐象辉. 犀角地黄汤联合西药对脓毒症凝血功能障碍患者临床疗效、凝血指标及预后的影响[J]. 中国医学创新,2019,16(16):116-119. |
| [4] | SINGER M,DEUTSCHMAN C S,SEYMOUR C W,et al.The third international consensus definitions for sepsis and septic shock(Sepsis-3)[J]. JAMA,2016,315(8):801-810. |
| [5] | 宋辉,孔飞飞,刘旋,等. 网织血小板及其相关参数在儿童免疫性血小板减少症及脓毒症中的应用[J]. 检验医学,2018,33(7):626-628 |
| [6] | 王建立. β受体阻滞剂治疗脓毒症相关心功能不全的临床疗效及预后分析[J]. 世界临床医学,2017,11(7):90. |
| [7] | 张志彪,严丽. PCT、LAC/ScvO2比值对脓毒症患者病情危重程度与预后的评估价值[J]. 临床急诊杂志,2019,20(2):119-123. |
| [8] | KOWAL-VERN A,ORKIN B A.Antithrombin in the treatment of burn trauma[J]. World J Crit Care Med,2016,5(1):17-26. |
| [9] | 张翠. 微小RNA-132和高迁移率族蛋白1在脓毒症患儿外周血单个核细胞中的表达及临床意义[J]. 检验医学,2018,33(9):815-818. |
| [10] | 许志平,马红玲,陈双峰,等. MCP-1和mHLA-DR检测对脓毒症患者病情危重程度及预后评估的临床意义[J]. 中华重症医学电子杂志(网络版),2019,5(3):225-229. |
| [11] | TANRIVERDI H,TOR M M,KART L,et al.Prognostic value of serum procalcitonin and C-reactive protein levels in critically ill patients who developed ventilator-associated pneumonia[J]. Ann Thorac Med,2015,10(2):137-142. |
| [12] | MATSUMOTO S,SUDA K,IIMOTO S,et al.Prospective study of deep vein thrombosis in patients with spinal cord injury not receiving anticoagulant therapy[J]. Spinal Cord,2015,53(4):306-309. |
| [13] | PRUCHA M,BELLINGAN G,ZAZULA R.Sepsis biomarkers[J]. Clin Chim Acta,2015,440:97-103. |
| [14] | SINGH B,HANSON A C,ALHURANI R,et al.Trends in the incidence and outcomes of disseminated intravascular coagulation in critically ill patients(2004-2010):a population-based study[J]. Chest,2013,143(5):1235-1242. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
